Skip to main content
Equibles
IXHL logo

IXHL · Incannex Healthcare Inc.

Track IXHL — free

Use IXHL with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$3.24 +0.06 (+1.89%) At close · Sep 2
Rebalance outlook locked
Market Cap
$38.05M
Shares
11.96M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.18 Open$3.35 Day$3.17–3.40 Since split$2.56–5.97 Avg vol 30d92K Short int812K · 6.8% float · 8.5d Short vol73% DataFeb 2026–Sep 2026 Filing10-Q · May 15

Raw chart and full-history price indicators begin at the captured split on Feb 27, 2026; bars on opposite sides are not compared.

The closing range begins at the captured split on Feb 27, 2026.

Up next

FQ1-27 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed May 15, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$48.41M
Trailing 12 months
Revenue growth YoY
+616.7%
Year over year
Operating margin
-27,661.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1,786.9%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
6.8%
Latest settlement · 8.5 days to cover
View all 114 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Neutral Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 16.3 · calm Equity put/call 0.67
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 50-day avg −4%
below
RSI (14) 41
neutral
MACD trend Negative
52-week position 18%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +7%
trailing
6-month return −47%
trailing
Relative strength −59%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Distributing
-29% holders QoQ · +6 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
6.79% of float · ▼ -8.2% MoM · 8.5 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
15 holders — mid 2-yr range
Squeeze score 60
elevated · 0–100
Fundamentals
Poor
EPS growth −17%
Y/Y
Free cash flow $-12.5M
Quant / Vol
risk profile
Very High
Volatility 111%
annualized · 1-yr
Max drawdown −57%
past year
ATR 6.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
1 · 5 · 0
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
−4% Neutral
RSI (14)
41 Neutral
MACD trend
Negative Bearish
52-week position
18% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Distributing
-29% holders QoQ · +6 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
6.79% of float · ▼ -8.2% MoM · 8.5 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
15 holders — mid 2-yr range
Price context
position in its range since split · 2026-02-27
Range low $3 Now $3 · 18% Range high $6
vs 50-day avg -4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
IXHL
Incannex Healthcare Inc.
this stock
$38.05M — +616.7% — 6.8%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
 $66.37B — — — 0.0%
TAK
Takeda Pharmaceutical Co Ltd
 $58.66B +16.9% — — 0.1%
GALDY
Galderma Group AG/ADR
 $47.69B -1.4% — — 0.0%
HLN
Haleon plc
 $44.35B -0.4% — — 0.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
15
% held
3.9%
Net QoQ
-820.2K sh
Top holder
LPL Financial LLC
Held Float
View
Held by Funds
Fund positions
5
View
Short & Settlement
Short Interest Falling
Shares short
812.5K
Days to cover
8.5d
Change
-72.2K sh
View
Short Volume
Short vol %
73%
As of
Sep 2, 2026
Short Total
View
Fails to Deliver
FTD shares
36
Value
$114
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
56.1%
Week of
Jul 27, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$12.0K
Net income (FY)
$-46.9M
EPS diluted
$-40.50
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 25, 2026
This year
23
View
Exempt Offerings
Offering
$12.5M
Filed
Mar 17, 2025
View

Performance

Raw-price comparisons begin at the captured split on Feb 27, 2026; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
IXHL -15.2% +7.1% -46.7% -5.1% —
SPY -0.5% -1.2% +12.6% -0.7% +11.7%
vs SPY -14.7% +8.3% -59.4% -4.4% —
Key facts CIK 1873875 CUSIP 45333F208 13F (30d) 14 filings 14 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)